about
Design, synthesis, and biological evaluation of potent c-Met inhibitorsDiscovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitorsStructure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitorsTotal Synthesis of Luzopeptin E2 This work was supported by the NIH (CA-55268), the NSF (CHE 95-26183), the R. A. Welch Foundation (C-1007), the A. P.Sloan Foundation (fellowship to M.A.C., 1994-1998), the MENRT, the CNRS, and the Région Rhône-AlpesStructure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-DPhe-Arg-Trp-Lys]-NH(2).Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists.N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.Noncovalent Interactions of Fluorine with Amide and CH Groups in N-Phenyl γ-Lactams: Covalently Identical Fluorine Atoms in Nonequivalent Chemical EnvironmentsStudies toward Luzopeptins: Assembly of the Elusive Serine-PCA Dipeptide
P50
Q27651910-2094619C-A634-429A-8E8D-EAFC7B22744DQ27666746-CC8964BB-58D9-420D-9526-4B84CA118F4EQ27677170-38845E3A-15BD-4A36-ACD6-35A0D4641ADDQ28277607-FDF8A111-E87C-408B-B344-032E9B75BF3BQ30607738-0BB0825C-BCCC-433D-977F-67D413AD9360Q39399221-FBBC570E-B885-4AF9-8131-7027C403013EQ44489578-B402C7B0-0DC9-4F39-8A9B-B89E1BD04F62Q45235581-2D9D5FAE-0906-4667-B9C3-BE4B6223740BQ46540377-E657EE38-091B-4A71-8FF1-E2EAC1CA8A9BQ46734697-9D1D10AD-FE55-4C12-B617-BCE9EF35E0AAQ47653706-FAA4CFB3-4B54-46CB-ABBC-B0C79BC9D602Q56983336-6EBDB651-36ED-4AF8-ACA3-BE055D323B12Q74835846-9C5AE833-61B0-4D5F-89E6-49F236E8BA11
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ning Xi
@ast
Ning Xi
@en
Ning Xi
@es
Ning Xi
@nl
type
label
Ning Xi
@ast
Ning Xi
@en
Ning Xi
@es
Ning Xi
@nl
prefLabel
Ning Xi
@ast
Ning Xi
@en
Ning Xi
@es
Ning Xi
@nl
P106
P1153
35081548700
57124499900
P31
P496
0000-0002-6468-8831